Molecular Staging

Molecular Staging is addressing this demand with a portfolio of products and services based on technologies that are transforming the detection and measurement of both proteins and nucleic acids.

  • NEW HAVEN, October 8, 2001 /– Molecular Staging Inc. (MSI) announced today that it received a Small Business Innovative Research (SBIR) grant to develop a method of detecting rare Human Papillomavirus (HPV) transformed cells using Rolling Circle Amplification Technology (RCATTM).
    Read the rest of this entry »

    Comments Off on Molecular Staging Inc. Receives SBIR Grant From The National Cancer Institute
  • NEW
    HAVEN, September 27, 2001/– Molecular Staging Inc.
    (MSI) announced today that it has been awarded two
    additional patents for Rolling Circle Amplification
    Technology (RCATTM).

    This further expands the
    intellectual property estate surrounding MSI’s Rolling
    Circle Amplification Technology to a total of 11 issued
    patents, including eight U.S. patents and three
    international patents.

    Rolling Circle
    Amplification Technology detects and measures proteins as
    well as nucleic acids with unprecedented sensitivity and
    expanded multiplexing capabilities.

    Read the rest of this entry »

    Comments Off on Molecular Staging Inc. Awarded Two Additional Patents For Rolling Circle Amplification Technology
  • NEW HAVEN,
    September 11, 2001  / —
    Molecular Staging Inc. (MSI) announced today that it had been granted
    a US Patent (6,280,949) covering Multiple Displacement Amplification
    technology (MDATM) and it’s use in life science research
    and diagnostic products.  This is the second patent granted for Multiple Displacement
    Amplification, invented by Dr. Paul Lizardi and colleagues at Yale
    University and exclusively licensed by MSI.

    Read the rest of this entry »

    Comments Off on Molecular Staging Inc granted a US Patent covering
  • Patents Issued in US, Europe, and Australia further expands Molecular Staging Inc.’s Rolling Circle Amplification Technology Patent Portfolio

    NEW HAVEN, September 5, 2001 / — Molecular Staging Inc. (MSI) announced today that it has received 6 US patents covering Rolling Circle Amplification Technology (RCATTM) and its use in life science research and diagnostic products. The United States Patent and Trademark Office (USPTO) awarded MSI patent numbers 06210884, 06183960, and 05854033 for “Rolling Circle Replication Reporter System”, and patent number 06143495 for “Unimolecular Segment Amplification & Sequencing” by RCAT.
    Read the rest of this entry »

    Comments Off on Molecular Staging Inc. Awarded Six U.S. Patents and Three International Patents
  • A highly sensitive and practical alternative amplification method is being developed for use in drug discovery and genetic analysis. Through an agreement between Molecular Staging Inc. and Amersham Pharmacia Biotech, Amersham Pharmacia Biotech has gained exclusive rights to commercialise reagents for all research uses of the new and revolutionary amplification procedure.
    Read the rest of this entry »

    Comments Off on Revolutionary Amplification Technology for Drug Discovery Goes Molecular
  • Q: In March of last year you published a complete genetic sequence for Drosophila melanogaster. How does it feel, at the end of the 20th century, to complete one of the tasks begun by American scientist Thomas Hunt Morgan at the beginning of the century?

    DR. RUBIN: It’s been very rewarding for me for a number of reasons. One reason is just finally getting it completed, as I’ve been working on it since 1992. The project has been more involved and a little more difficult than I originally expected. I feel satisfied that it’s almost done, and when it is, I’ll be able to move on with my life. Read the rest of this entry »

    Comments Off on Genetic sequence for Drosophila melanogaster
  • genetic-ancestryQ: You’ve written about how genomics will shed light on many evolutionary puzzles. What are some examples?

    DR. KING: One example of enormous interest to me is what makes us human. As a species we became human because genetic changes occurred that enabled us to build a culture, and eventually cultural evolution became our most obvious feature. Read the rest of this entry »

    Comments Off on Genetic ancestry
  • Cancer genetics moving forward

    Q: Do you think improvements in tumor classification are going to prove essential to the process of breast cancer diagnosis and therapy?

    DR. KING: I do think it’s important. I think that the approaches being used, from morphology to protein markers to RNA expression profiles, are all useful.

    A very promising next step will be to develop treatments that work for reasons that we understand against one subset of tumors as defined either by their protein profiles, their morphology, their DNA expression profiles, or their somatic alterations—or some combinations thereof. Read the rest of this entry »

    Comments Off on Cancer genetics moving forward
  • brca1Q: What happens that allows mutations in BRCA1 and BRCA2 to lead to cancer rather than causing cell death

    DR. KING: That’s the other big puzzle in this field because these are genes involved in critical pathways. It was clear from very early knockout work that these genes are critical for development. The full knockouts were early embryonic lethals. So why do we ever see tumor development? It’s now clear that p53 may play a role in which alterations of p53 may modify the consequence of the knockout of BRCA1. It may well be the case that there is some small subset of cells, which even if the gene is knocked out, don’t die. Read the rest of this entry »

    Comments Off on What happens that allows mutations in BRCA1 and BRCA2 ?
  • 71085840Q: For twenty years you hammered out the problem of gene-specific causation and were finally able to identify genes associated with breast cancer, BRCA1 and then BRCA2. How are these discoveries affecting breast cancer research?

    DR. KING: I think the discoveries have had two different effects. First and most obviously they have an enormous, direct, clinical, and practical impact on women who carry these mutations. I think there’s no controversy now that BRCA1 and BRCA2 are the major breast cancer genes. Both BRCA1 and BRCA2 have a vast number of different protein-truncating mutations that abrogate their normal functions. But there still remains a great deal of controversy about just what risks for breast cancer and for ovarian cancer are associated with mutations in these genes. Read the rest of this entry »

    Comments Off on Breast cancer breakthroughs